A B9 lesion is medical shorthand for a benign lesion, meaning a growth or abnormal area of tissue that is not cancerous. You’ll most often see “B9” as an abbreviation on medical billing codes, radiology reports, or clinical notes where space is limited. It is not a separate classification system or diagnosis on its own. It simply means the lesion has been evaluated and determined to be noncancerous.
Where the Term “B9” Comes From
In medical coding and clinical shorthand, “B9” is a common abbreviation for “benign.” You can find it in procedure codes used for insurance billing, such as those describing the excision of a benign skin lesion. For example, a billing code might read “EXC B9 LESION” rather than spelling out the full word. If you’ve spotted “B9” on paperwork from a dermatologist visit, a surgical note, or an imaging report, it’s this shorthand at work.
It’s worth noting that “B9” is different from the B-code classification system used in breast pathology in the United Kingdom. That system uses categories B1 through B5 to classify biopsy results, where B2 means benign and B5 means malignant. There is no B9 category in that system. The “B9” you’re reading almost certainly just means “benign.”
What Makes a Lesion Benign
A benign lesion is a collection of abnormal cells that multiply more than normal cells but lack the defining features of cancer. Benign growths tend to be slow-growing and stay put. They don’t invade surrounding tissue or spread to distant parts of the body. On imaging, they typically appear with smooth, well-defined borders, an oval or round shape, and limited blood flow. These features help radiologists distinguish them from suspicious or malignant growths, which tend to have irregular edges and a more aggressive blood supply.
When a pathologist examines tissue under a microscope, benign cells look relatively normal and organized compared to cancerous cells. Reports may describe the tissue as “without atypia,” meaning the cells don’t have the unusual, disorganized appearance associated with cancer.
Common Types of Benign Lesions
Benign lesions can appear almost anywhere in the body. Some of the most frequently diagnosed types include:
- Lipomas: Soft, movable lumps under the skin caused by fatty deposits. They commonly appear on the forearms, torso, and back of the neck.
- Seborrheic keratoses: Waxy, raised skin growths that are extremely common with age and are harmless despite sometimes looking alarming.
- Cysts: Fluid-filled sacs that can develop in the skin, breasts, kidneys, and other organs. Simple cysts with no unusual features are reliably benign.
- Fibroadenomas: The most common benign tumor in the breast, made of a mix of glandular and connective tissue.
- Dermoid cysts: Unusual benign tumors that can contain hair, sweat glands, oil glands, and occasionally cartilage or bone fragments.
- Dermatofibromas: Small, firm bumps in the skin that develop after minor injuries like insect bites.
How a Benign Diagnosis Is Made
A lesion can be classified as benign through imaging alone or through a biopsy, depending on how confident your doctor is based on its appearance. On ultrasound, MRI, or CT scans, radiologists look for the hallmarks of a benign growth: smooth margins, uniform internal structure, and minimal blood flow. An adrenal mass that shows features of a common benign type like a myelolipoma (containing visible fat) or a simple cyst (fluid-filled with no enhancement) needs no further workup at all.
When imaging isn’t definitive, a biopsy provides a tissue sample for a pathologist to examine. In breast pathology, for instance, your report might list terms like fibrocystic changes, adenosis, cysts, or columnar cell change. All of these are benign findings. If the pathologist sees something less clear-cut, such as a growth that could be a fibroadenoma or a rarer tumor type, they may use broader descriptions like “benign fibroepithelial neoplasm” to indicate it’s noncancerous but warrants closer attention.
Risk of a Benign Lesion Becoming Cancer
The vast majority of lesions classified as benign stay benign. When imaging criteria are applied correctly, more than 98% of lesions rated as “probably benign” on mammography turn out to be noncancerous. In a multi-center study of breast MRI findings, malignancy was ultimately diagnosed in only 0.9% of lesions initially classified as probably benign, and in that single case, the cancer found was an early, non-invasive form.
Certain benign conditions do carry a slightly elevated long-term risk. Atypical ductal hyperplasia and atypical lobular hyperplasia, for example, are not cancer but are associated with a modestly higher chance of developing cancer in the future. If your pathology report mentions atypia, your doctor will likely recommend closer monitoring. A straightforward benign finding without atypia, however, carries very low risk.
When a Benign Lesion Needs Treatment
Most benign lesions don’t require any treatment. You and your doctor might decide to remove one if it’s causing symptoms like pain, bleeding, or pressure on surrounding tissue. Cosmetic concerns are another common reason, particularly for visible skin growths. Pyogenic granulomas, for instance, are typically removed because they grow quickly and bleed easily, even though they’re benign.
Lesions that change in size, shape, or color may also warrant removal or biopsy to make sure they haven’t developed atypical features. For skin growths like seborrheic keratoses, dermatofibromas, or sebaceous hyperplasia, no treatment is needed unless they become irritated or you simply want them gone.
Follow-Up After a Benign Diagnosis
Follow-up depends on the type and location of the lesion. Many benign findings need no monitoring at all. Simple cysts in the kidney, for example, classified as the lowest-risk types on imaging, require no follow-up. An adrenal mass that has remained stable for a year or longer is considered very likely benign and doesn’t need additional imaging.
For lesions classified as “probably benign” rather than definitively benign, your doctor may recommend a short-interval follow-up scan, often at six months, to confirm the growth hasn’t changed. If it stays the same or shrinks, it’s reclassified as benign and routine screening resumes. This watch-and-wait approach avoids unnecessary biopsies while keeping a close eye on anything that could evolve.